Leerink, TD Cowen and LifeSci Capital are acting as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma upgraded to Outperform from Market Perform at Citizens
- Sutro Biopharma: Transition to STRO-004–Driven Clinical Execution Warrants Hold as Long-Term Upside Meets Near-Term Uncertainty
- Sutro Biopharma Regains Nasdaq Listing Compliance
- Sutro Biopharma regains compliance with Nasdaq
- Sutro Biopharma price target raised to $51 from $5 at Deutsche Bank